Date: 2014-01-08
Type of information: R&D agreement
Compound:
Company: Bayer (Germany) Peking University (China)
Therapeutic area: Cardiovascular diseases - Cancer - Oncology - Hematological diseases -
Type agreement: R&D
Action mechanism:
Disease:
Details:
* On January 8, 2014, Bayer HealthCare and Peking University have signed a comprehensive collaboration agreement on a three-year strategic partnership to promote translational research for drug discovery. Under this agreement, the two partners will establish a joint research center at Peking University under the name Bayer HealthCare/Peking University Center of Translational Research for Drug Discovery (BPC/TRDD).
The collaboration will focus on applying basic research to drug discovery in the therapeutic areas of cardiology, oncology, hematology, and gynecological therapy, as well as technological research along the drug-discovery and -development value chain. Through this collaboration, scientists at PKU and BHC will be able to work together on the discovery of new medicines and contribute to the innovation landscape in China.
The Bayer HealthCare/Peking University Center of Translational Research for Drug Discovery will serve as a platform enabling scientists in life-sciences-related schools - such as the School of Life Sciences & Institute of Molecular Medicine and the School of Chemical Biology & Biotechnology and other affiliations at Peking University ¬- to collaborate with scientists at Bayer HealthCare Global Drug Discovery.
As part of the agreement with Peking University, Bayer HealthCare will provide funding for collaborative research projects. In addition, Bayer will sponsor a Bayer Professorship and Bayer Investigator Awards to promote and reward scientific excellence, important contributions to life sciences, and research that is beneficial to drug discovery, especially in the fields of Bayer HealthCare’s core therapeutic areas.
The strategic partnership with Peking University further underlines Bayer HealthCare’s ongoing commitment to China as an important location in its innovation strategy. Bayer HealthCare’s Innovation Center China was established as early as 2009 as part of its R&D Center China to strengthen the company’s global research-and-development capabilities and to include the clinical profiles and medical needs of Asian patients early on in its drug development activities.
Financial terms:
Latest news:
